SeaStar Medical Holding Corporation, a company listed on The Nasdaq Stock Market under the trading symbol ICU, held a virtual Special Meeting of stockholders on June 4, 2024. During the meeting, stockholders voted on several key proposals. Three Class II Directors were elected to serve until the 2027 annual meeting: Allan Collins, MD, Jennifer A. Baird, and Bernadette N. Vincent. An amendment and restatement of the Company's 2022 Omnibus Equity Incentive Plan was approved, increasing the authorized shares of common stock from 3,278,457 to 9,778,457. Additionally, the issuance of more than 20% of the Company's outstanding shares of Common Stock upon exercise of Series A and Series B Warrants was approved, in compliance with Nasdaq Listing Rule 5635(d). The appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was also ratified.

SeaStar Medical Holding Corporation, a company listed on The Nasdaq Stock Market under the trading symbol ICU, held a virtual Special Meeting of stockholders on June 4, 2024. During the meeting, stockholders voted on several key proposals. Three Class II Directors were elected to serve until the 2027 annual meeting: Allan Collins, MD, Jennifer A. Baird, and Bernadette N. Vincent. An amendment and restatement of the Company's 2022 Omnibus Equity Incentive Plan was approved, increasing the authorized shares of common stock from 3,278,457 to 9,778,457. Additionally, the issuance of more than 20% of the Company's outstanding shares of Common Stock upon exercise of Series A and Series B Warrants was approved, in compliance with Nasdaq Listing Rule 5635(d). The appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was also ratified.